CD8A and cancer: Antitumor immune responses of cancer vaccines are based on the recognition of antigens by professional antigen-presenting cells (APCs) and the activation or initiation of naive antigen-specific T cells, especially CD8+ cytotoxic T lymphocytes (CTLs)[2].